Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds
-
Vijay Kumar Vishvakarma
, Prashant Singh, Monica Dubey
, Kamlesh Kumari , Ramesh Chandra and Narender D. Pandey
Abstract
Background: Type 2 diabetes is the most common form of diabetes, accounting for over 90% of cases. Current treatment approaches for type 2 diabetes include diet, exercise, and a variety of pharmacologic agents, including insulin, biguanides, sulfonylureas, and thiazolidinediones.
Methods: In the present scenario, researchers focused themselves on thiazolidine ring-based compounds to cure type 2 diabetes mellitus. Among the peroxisome proliferator activated receptor (PPAR) family, PPAR-γ is the most effective in curing glucose homeostasis.
Results and conclusions: Thiazolidine ring-based compounds act as PPAR-γ agonists, and herein, we have successfully developed nine derivatives of thiazolidine ring-based compounds that are found to be biologically potent using two-dimensional quantitative structure-activity relationship model.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: The authors acknowledge the Department of Science and Technology and the University Grant Commission for their financial support.
Employment or leadership: The corresponding author is an employee at Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
Honorarium: None declared.
References
1. Centers for Disease Control and Prevention. National Diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Department of Health and Human Services. Centers for Disease Control and Prevention, 2008.Search in Google Scholar
2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care J 2007;30(Suppl 1):S4–41.10.2337/dc07-S004Search in Google Scholar PubMed
3. Prashant S, Kamlesh K, Gaurav K, Gopal KM. Efficient one-pot four-component synthesis of fused thiazolopyridin-2-ones in ionic liquid. J Chem Sci 2012, in press.Search in Google Scholar
4. Prashant S, Kamlesh K, Monica D, Vijay KV, Narendera DP, Ramesh C, et al. Ionic liquid catalyzed synthesis of 7-phenyl-1,4,6,7-tetrahydro-thiazolo[5,4-d] pyrimidine-2,5-diones. C R Chimie 2012;15:504–10.10.1016/j.crci.2012.04.002Search in Google Scholar
5. Kamlesh K, Prashant S, Monica D, Narendera DP, Ramesh C, Gopal KM. A catalyst free convenient one pot synthesis of multisubstituted chromeno-thiazolones. C R Chimie 2012;15:267–72.10.1016/j.crci.2011.12.004Search in Google Scholar
6. Prashant S, Kamlesh K, Vartika T, Mohd S, Rajan P, Gopal KM, et al. A novel method to chemically bind the thiazolidine-2,4-dione through cross linked chitosan nanoparticles using malanodialdehyde as a cross linker. Can J Chem 2011;89:1–11.Search in Google Scholar
7. Pradip K, Prankaj K, Jagvir S, Prashant S, Ramesh C. Synthesis and evaluation of antimicrobial activity of 8-phenyl-3,4,7,8-tetrahydrobisthiazolopyridine-2,6-dione derivatives. J Chem Asia 2011;2:101–14.Search in Google Scholar
8. Prashant S, Pradeep K, Anju K, Rashmi K, Sujata KD, Satya P, et al. Synthesis and electrochemical studies of charge transfer complexes of thiazolidine-2, 4-dione with sigma and pi acceptors. Spectrochim Acta A Mol Biomol Spectrosc 2010;75:983–91.10.1016/j.saa.2009.12.019Search in Google Scholar PubMed
9. Prashant S, Kamlesh K, Anju K, Rashmi K, Ramesh C. Copper nanoparticles in ionic liquid: an easy and efficient catalyst for selective Cara-Michael addition reaction. Catal Lett 2009;127:119–25.10.1007/s10562-008-9654-7Search in Google Scholar
10. Prashant S, Kamlesh K, Anju K, Rashmi K, Ramesh C. Cu nanoparticles in ionic liquid: an easy and efficient catalyst for addition-elimination reaction between active methylene compounds and imines in an ionic liquid. Catal Lett 2009;130:648–54.10.1007/s10562-009-9944-8Search in Google Scholar
11. Prashant S, Anju K, Rashmi K, Ramesh C. Copper nanoparticles in ionic liquid: an easy and efficient catalyst for the coupling of thiazolidine-2,4-dione, aromatic aldehyde and ammonium acetate. Catal Commun 2008;9:1618–23.10.1016/j.catcom.2008.01.010Search in Google Scholar
12. Prashant S, Anju K, Rashmi K, Ramesh C. Copper nanoparticles in an ionic liquid: an efficient catalyst for the synthesis of bis-(4-hydroxy-2-oxothiazolyl)methanes. Tetrahedron Lett 2008;49:727–30.10.1016/j.tetlet.2007.11.106Search in Google Scholar
13. Ajeet K, Prashant S, Amit S, Arnab D, Ramesh C, Subho M. Nano-sized copper as an efficient catalyst for one pot three component synthesis of thiazolidine-2, 4-dione derivatives. Catal Commun 2008;10:17–22.10.1016/j.catcom.2008.07.030Search in Google Scholar
14. Ibrahimi A, Teboul L, Gaillard D, Amri EZ, Ailhaud G, Young P, et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in pre-adipose cells. Mol Pharmacol 1994;46:1070–6.Search in Google Scholar
15. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393–8.Search in Google Scholar
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953–6.10.1074/jbc.270.22.12953Search in Google Scholar PubMed
17. Komers R, Vrana A. Thiazolidinediones—tools for the research of metabolic syndrome X. Physiol Res 1998;47:215–25.Search in Google Scholar
18. Evans RM, Barish GD, Wang Y-X. PPARs and the complex journey to obesity. Nat Med 2004;10:355–61.10.1038/nm1025Search in Google Scholar
19. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43: 527–50.10.1021/jm990554gSearch in Google Scholar
20. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409–35.10.1146/annurev.med.53.082901.104018Search in Google Scholar
21. Hansch C, Leo A. Substituent constants for correlation analysis in chemistry and biology. New York: John Wiley & Sons, 1979.Search in Google Scholar
22. Rathi L, Kashaw SK, Dixit A, Pandey G, Saxena AK. Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-l-tyrosines as PPAR gamma agonists. Bioorg Med Chem 2004;12:63–9.10.1016/j.bmc.2003.10.032Search in Google Scholar
23. Liao C, Xie A, Shi L, Zhou J, Lu X. Eigenvalue analysis of peroxisome proliferator-activated receptor gamma agonists. J Chem Inf Comput Sci 2004;44:230–8.10.1021/ci034109cSearch in Google Scholar
24. Hyun KH, Lee DY, Lee B, Kim CK. Receptor-based 3D QSAR studies on PPARgamma agonists using CoMFA and CoMSIA approaches. QSAR Comb Sci 2004;23:637–49.10.1002/qsar.200430878Search in Google Scholar
25. Kurogi Y. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones. Drug Des Discov 1999;16:109–18.Search in Google Scholar
26. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, et al. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822–9.10.1002/art.24761Search in Google Scholar
27. Rucker C, Scarsi M, Meringer M. 2D QSAR of PPARgamma agonist binding and transactivation. Bioorg Med Chem 2006;14:5178–95.10.1016/j.bmc.2006.04.005Search in Google Scholar
28. Kulkarni SS, Gediya LK, Kulkarni VM. Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. Bioorg Med Chem 1999;7:1475–85.10.1016/S0968-0896(99)00063-2Search in Google Scholar
29. Sotriffer CA, Winger RH, Liedl KR, Rode Bernd M, Varga JM. Comparative docking studies on ligand binding to the multispecific antibodies IgE-La2 and IgE-Lb4. J Comput Aided Mol Des 1996;10:305–20.10.1007/BF00124500Search in Google Scholar PubMed
30. Brass LF. Thrombin and platelet activation. Chest 2003;124:3(Suppl):18S–25S.10.1378/chest.124.3_suppl.18SSearch in Google Scholar
31. Rubenstein LA, Lanzara RG. Activation of G protein-coupled receptors entails cysteine modulation of agonist binding. J Mol Struct (Theochem) 1998;430:57–71.10.1016/S0166-1280(98)90217-2Search in Google Scholar
32. Raymond V, Sattelle DB. Novel animal-health drug targets from ligand-gated chloride channels. Nat Rev Drug Discov 2002;1:427–36.10.1038/nrd821Search in Google Scholar
33. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008;21:659–67.10.1097/QCO.0b013e328318978fSearch in Google Scholar
34. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotech 2011;29:1039–45.10.1038/nbt.2017Search in Google Scholar
35. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech 2011;29:1046–51.10.1038/nbt.1990Search in Google Scholar
36. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753–8.10.1038/39645Search in Google Scholar
37. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003;330:1005–14.10.1016/S0022-2836(03)00662-4Search in Google Scholar
38. Katz AH, Caufield CE. Structure-based design approaches to cell wall biosynthesis inhibitors. Current Pharm Des 2003;9:857–66.10.2174/1381612033455305Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
Articles in the same Issue
- Masthead
- Masthead
- Editorial
- Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnical and regulatory aspects
- Opinion Paper
- An ethical framework for the disposal of autologous stem cells
- Original Articles
- A prospective observational study of medication errors in general medicine department in a tertiary care hospital
- Regulatory polymorphisms in CYP2C19 affecting hepatic expression
- Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds
- Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
- CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control
- Congress Abstracts
- Post-Congress Satellite Meeting/Pharmacogenomics and theranostics in practice
Articles in the same Issue
- Masthead
- Masthead
- Editorial
- Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnical and regulatory aspects
- Opinion Paper
- An ethical framework for the disposal of autologous stem cells
- Original Articles
- A prospective observational study of medication errors in general medicine department in a tertiary care hospital
- Regulatory polymorphisms in CYP2C19 affecting hepatic expression
- Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds
- Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
- CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control
- Congress Abstracts
- Post-Congress Satellite Meeting/Pharmacogenomics and theranostics in practice